MarketMoodz
Trump administration finalizes 2.48% 2027 Medicare Advantage rate; insurers rally
The CMS has finalized a 2.48% Medicare Advantage payment rate for 2027, beating January’s proposed 0.09% increase and paving the way for higher MA funding. Investors piled into MA players after-hours, lifting UnitedHealth, CVS Health, and Humana shares as the news circulated.
Key Takeaways
- CMS sets 2027 Medicare Advantage rate at 2.48%, vs. 0.09% proposed in January
- Rate is expected to raise MA payments by more than $13 billion
- UNH, CVS, and HUM rallied in after-hours trading, signaling investor optimism
- Rate affects MA premiums, benefits, and insurer margins
People Involved
- Chiquita Brooks-LaSureCMS Administrator
Entities Involved
- UnitedHealth Group (UNH)MA insurer and healthcare services company
- CVS Health (CVS)MA insurer and pharmacy benefits manager
- Humana (HUM)MA insurer
MarketMoodz Analysis
Investors welcomed the 2.48% increase, which tightens MA insurers' funding and can support richer plan benefits or more favorable premium pricing. The after-hours surge in UNH, CVS, and HUM suggests the market expects higher margins and potentially higher near-term earnings for MA plans.
This outcome occurs within a broader policy debate over MA benchmarking, risk adjustment, and potential overpayments. Historically, MA payments have swung with congressional and CMS policy shifts, so investors should watch for near-term policy reviews and any shifts in how CMS calibrates risk scores and enrollment dynamics. Look for updates on enrollment trends, provider networks, and drug-benefit management as these factors will influence how insurers translate the rate into actual products for beneficiaries.
Source: Original Article